The DOI matches its Crossref record; 26 of the 28 references it cites were found in a registry or an index.
Identification of the Nicotinic Receptor Subtypes Expressed on Dopaminergic Terminals in the Rat Striatum
Open accessAbstract
Neuronal nicotinic acetylcholine receptors (nAChRs) expressed on mesostriatal dopaminergic neurons are thought to mediate several behavioral effects of nicotine, including locomotion, habit learning, and reinforcement. Using immunoprecipitation and ligand-binding techniques, we have shown that both alpha6beta2* and alpha4(nonalpha6)beta2* nAChRs are expressed in the caudate-putamen and that only alpha6* nAChRs can bind alpha-conotoxin MII and methyllycaconitine with affinities of 1.3 and 40 nm, respectively. Further studies performed on 6-hydroxydopamine-lesioned striatum led to the identification of nAChR subtypes selectively expressed on dopaminergic terminals [alpha4alpha5beta2, alpha4alpha6beta2(beta3), and alpha6beta2(beta3)], nondopaminergic neuronal structures (alpha2alpha4beta2), or both structures (alpha4beta2). The identification of the nAChRs expressed on striatal dopaminergic terminals opens up the possibility of developing selective nAChR ligands active on dopaminergic systems and associated diseases, such as Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“DA neurons express heteromeric nAChRs containing the α4, α5, α6, β2, and β3 subunits in various combinations, with the predominant subtypes being α4/β2/α5 and α4/α6/ β2/β3.”
From Mechanisms of Nicotine Addiction (2021) · cites this paper as Zoli et al. 2002
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LIGAND: A versatile computerized approach for characterization of ligand-binding systems
Munson, P. J., & Rodbard, D. (1980) · Analytical Biochemistry · doi:10.1016/0003-2697(80)90515-1 · Cited by 8,373
Picciotto, M. R., Zoli, M., Rimondini, R., Léna, C., Marubio, L. M., Pich, E. M., Fuxe, K., & Changeux, J.-P. (1998) · Nature · doi:10.1038/34413 · Cited by 1,320
Self-citationNicotinic Receptors at the Amino Acid Level
Corringer, P., Novère, N. G. L., & Changeux, J. (2000) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.431 · Cited by 832
Role of dopamine in the behavioural actions of nicotine related to addiction
Chiara, G. D. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00122-9 · Cited by 698
Klink, R., d'Exaerde, A. D. K., Zoli, M., & Changeux, J.-P. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01452.2001 · Cited by 674
Self-citationEndogenous nicotinic cholinergic activity regulates dopamine release in the striatum
Zhou, F.-M., Liang, Y., & Dani, J. A. (2001) · Nature Neuroscience · doi:10.1038/nn769 · Cited by 585
A New α-Conotoxin Which Targets α3β2 Nicotinic Acetylcholine Receptors
Cartier, G. E., Yoshikami, D., Gray, W. R., Luo, S., Olivera, B. M., & McIntosh, J. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.13.7522 · Cited by 489
Self-citationNovère, N. L., & Changeux, J. (1995) · Journal of Molecular Evolution · doi:10.1007/bf00167110 · Cited by 429
Identification of four classes of brain nicotinic receptors using beta2 mutant mice.
Zoli, M., Léna, C., Picciotto, M. R., & Changeux, J. (1998) · PubMed Central · doi:10.1523/jneurosci.18-12-04461.1996 · Cited by 387
Self-citationLe Novere, N., Zoli, M., & Changeux, J. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01206.x · Cited by 385
Self-citation
Research works printed but not linked: 1
- Lindstrom J (2000) The structure of nAChRs. In: Neuronal nicotinic receptors, Handbook of experimental pharmacology, Vol 144 (Cle- menti F, Fornasari D, and Gotti C, eds), pp 101-162. Berlin: Springer.
Cited by
Sorted by citations
Items 101–200 of 410
Nicotinic acetylcholine receptors: an overview on drug discovery
D’hoedt, D., & Bertrand, D. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902841045 · Cited by 79
Maskell, P., Spéder, P., Newberry, N. R., & Bermúdez, I. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705559 · Cited by 80
Quarta, D., Ciruela, F., Patkar, K. A., Borycz, J., Solinas, M., Lluı́s, C., Franco, R., Wise, R. A., Goldberg, S. R., Hope, B. T., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301103 · Cited by 80
Papke, R. L., Dwoskin, L. P., Crooks, P. A., Zheng, G., Zhang, Z., McIntosh, J. M., & Stokes, C. R. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.03.010 · Cited by 79
Self-citationNicotinic acetylcholine receptor redux: Discovery of accessories opens therapeutic vistas
Matta, J. A., Gu, S., Davini, W. B., & Bredt, D. S. (2021) · Science · doi:10.1126/science.abg6539 · Cited by 75
Azam, L., Maskos, U., Changeux, J., Dowell, C. D., Christensen, S. B., Biasi, M. D., & McIntosh, J. M. (2010) · The FASEB Journal · doi:10.1096/fj.10-166272 · Cited by 77
Self-citationHIV, Tat and dopamine transmission
Gaskill, P. J., Miller, D. R., Gamble‐George, J., Yano, H., & Khoshbouei, H. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.04.015 · Cited by 78
Differential regulation of dopamine D1 and D2 signaling by nicotine in neostriatal neurons
Hamada, M., Higashi, H., Nairn, A. C., Greengard, P., & Nishi, A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02574.x · Cited by 78
Cytisine and cytisine derivatives. More than smoking cessation aids
Gotti, C., & Clementi, F. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105700 · Cited by 86
Self-citationAn autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutants
Baddick, C. G., & Marks, M. J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.04.019 · Cited by 75
Greenbaum, L., & Lerer, B. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.59 · Cited by 73
Tumkosit, P., Kuryatov, A., Luo, J., & Lindstrom, J. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.027326 · Cited by 73
Molecular biology and electrophysiology of neuronal nicotinic receptors of rat chromaffin cells
Angelantonio, S. D., Matteoni, C., Fabbretti, E., & Nistri, A. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02669.x · Cited by 71
Sanjakdar, S. S., Maldoon, P. P., Marks, M. J., Brunzell, D. H., Maskos, U., McIntosh, J. M., Bowers, M. S., & Damaj, M. I. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.177 · Cited by 74
Self-citationGotti, C., Moretti, M., Zanardi, A., Gaimarri, A., Champtiaux, N., Changeux, J., Whiteaker, P., Marks, M., Clementi, F., & Zoli, M. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.015925 · Cited by 72
Self-citationKing, S. L., Caldarone, B. J., & Picciotto, M. R. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.06.024 · Cited by 70
Mysterious α6-containing nAChRs: function, pharmacology, and pathophysiology
Yang, K., Jin, G.-Z., & Wu, J. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.63 · Cited by 69
Regulation of striatal dopamine release by presynaptic auto- and heteroreceptors
Zhang, H., & Sulzer, D. (2011) · Basal Ganglia · doi:10.1016/j.baga.2011.11.004 · Cited by 73
Modulation of dopamine release in the striatum by physiologically relevant levels of nicotine
Wang, L., Shang, S., Kang, X., Teng, S., Zhu, F., Liu, B., Wu, Q., Li, M., Liu, W. Y., Xu, H., et al. (2014) · Nature Communications · doi:10.1038/ncomms4925 · Cited by 69
Gotti, C., Moretti, M., Meinerz, N. M., Clementi, F., Gaimarri, A., Collins, A. C., & Marks, M. J. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.045203 · Cited by 68
Self-citationNagai, T., Ito, M., Nakamichi, N., Mizoguchi, H., Kamei, H., Fukakusa, A., Nabeshima, T., Takuma, K., & Yamada, K. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.3139-06.2006 · Cited by 67
Flatscher‐Bader, T., Zuvela, N. G., Landis, N., & Wilce, P. A. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm283 · Cited by 66
Srinivasan, R., Henley, B. M., Henderson, B. J., Indersmitten, T., Cohen, B. N., Kim, C. H., McKinney, S. L., Deshpande, P., Xiao, C., & Lester, H. A. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.2126-15.2016 · Cited by 61
Rose, E. J., Ross, T. J., Salmeron, B. J., Lee, M., Shakleya, D. M., Huestis, M. A., & Stein, E. A. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.013 · Cited by 67
From smoking to lung cancer: the CHRNA5/A3/B4 connection
Improgo, M. R., Scofield, M. D., Tapper, A. R., & Gardner, P. D. (2010) · Oncogene · doi:10.1038/onc.2010.256 · Cited by 67
Quaak, M., van Schayck, O. C. P., Knaapen, A. M., & van Schooten, F. (2009) · European Respiratory Journal · doi:10.1183/09031936.00056908 · Cited by 66
Effects of nicotine on homeostatic and hedonic components of food intake
Stojakovic, A., Espinosa, E. V. P., Farhad, O. T., & Lutfy, K. (2017) · Journal of Endocrinology · doi:10.1530/joe-17-0166 · Cited by 65
Grilli, M., Parodi, M., Raiteri, M., & Marchi, M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03126.x · Cited by 65
Cao, Y., Surowy, C. S., & Puttfarcken, P. S. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.09.005 · Cited by 65
Mugnaini, M., Garzotti, M., Sartori, I., Pilla, M. A., Repeto, P., Heidbreder, C. A., & Tessari, M. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.09.008 · Cited by 67
Loss of α‐conotoxinMII‐ and A85380‐sensitive nicotinic receptors in Parkinson's disease striatum
Quik, M., Bordia, T., Forno, L. S., & McIntosh, J. M. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02177.x · Cited by 62
Self-citationReduced striatal D 1 receptor binding in autosomal dominant nocturnal frontal lobe epilepsy
Fedi, M., Berkovic, S. F., Scheffer, I. E., O'Keefe, G. J., Marini, C., Mulligan, R. S., Gong, S., Tochon‐Danguy, H., & Reutens, D. C. (2008) · Neurology · doi:10.1212/01.wnl.0000316192.52731.77 · Cited by 62
Altered Striatal Function and Muscarinic Cholinergic Receptors in Acetylcholinesterase Knockout Mice
Volpicelli‐Daley, L. A., Hrabovská, A., Duysen, E. G., Ferguson, S. M., Blakely, R., Lockridge, O., & Levey, A. I. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.6.1309 · Cited by 62
Addiction‐related neuroadaptations following chronic nicotine exposure
Wills, L., & Kenny, P. J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15356 · Cited by 61
Bowers, B. J., McClure‐Begley, T. D., Keller, J. J., Paylor, R. E., Collins, A. C., & Wehner, J. M. (2005) · Alcoholism Clinical and Experimental Research · doi:10.1097/01.alc.0000156116.40817.a2 · Cited by 61
Marchi, M., & Grilli, M. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.004 · Cited by 61
Broadbent, S. D., Groot‐Kormelink, P. J., Krashia, P., Harkness, P. C., Millar, N. S., Beato, M., & Sivilotti, L. G. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.026682 · Cited by 60
Bruijnzeel, A. W., & Markou, A. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.05.005 · Cited by 62
Moretti, M., Mugnaini, M., Tessari, M., Zoli, M., Gaimarri, A., Manfredi, I., Pistillo, F., Clementi, F., & Gotti, C. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064071 · Cited by 58
Self-citationHeath, C. J., King, S. L., Gotti, C., Marks, M. J., & Picciotto, M. R. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.130 · Cited by 59
Self-citationThe effect of prenatal nicotine on expression of nicotine receptor subunits in the fetal brain.
Lv, J., Mao, C., Zhu, L.-Y., Zhang, H., Hui, P., Xu, F.-C., Liu, Y.-J., Zhang, L.-B., & Xu, Z.-C. (2008) · Neurotoxicology · doi:10.1016/j.neuro.2008.04.015 · Cited by 58
Meyer, E. L., Yoshikami, D., & McIntosh, J. M. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05266.x · Cited by 58
Self-citationTammimäki, A., Herder, P., Li, P., Esch, C., Laughlin, J. R., Akk, G., & Stitzel, J. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.022 · Cited by 61
Azam, L., & McIntosh, J. M. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.024513 · Cited by 56
Self-citationNicotinic receptor modulation to treat alcohol and drug dependence
Rahman, S., Engleman, E. A., & Bell, R. L. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00426 · Cited by 60
Nicotinic receptor-based therapeutics and candidates for smoking cessation
Dwoskin, L. P., Smith, A. M., Wooters, T. E., Zhang, Z., Crooks, P. A., & Bardo, M. T. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.06.002 · Cited by 57
Middleton, L. S., Cass, W. A., & Dwoskin, L. P. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055335 · Cited by 55
Acute Nicotine Differentially Impacts Anticipatory Valence- and Magnitude-Related Striatal Activity
Rose, E. J., Ross, T. J., Salmeron, B. J., Lee, M., Shakleya, D. M., Huestis, M. A., & Stein, E. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.034 · Cited by 59
Zarrindast, M., Naghdi-Sedeh, N., Nasehi, M., Sahraei, H., Bahrami, F., & Asadi, F. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.03.069 · Cited by 55
Khwaja, M., McCormack, A., McIntosh, J. M., Di Monte, D. A., & Quik, M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04177.x · Cited by 54
Self-citationCampanucci, V. A., Krishnaswamy, A., & Cooper, E. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.5130-07.2008 · Cited by 55
Lewis, S. J., Araya, R., Davey Smith, G., Freathy, R., Gunnell, D., Palmer, T., & Munafò, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021689 · Cited by 53
Nitrogen substitution modifies the activity of cytisine on neuronal nicotinic receptor subtypes
Carbonnelle, E., Sparatore, F., Canu, C., Salvagno, C., Baldani‐Guerra, B., Terstappen, G. C., Zwart, R., Vijverberg, H. P. M., Clementi, F., & Gotti, C. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01817-x · Cited by 54
Self-citationMcCallum, S. E., Parameswaran, N., Bordia, T., McIntosh, J. M., Grady, S. R., & Quik, M. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.012773 · Cited by 52
Self-citationKaradsheh, M. S., Shah, M. S., Tang, X., Macdonald, R. L., & Stitzel, J. A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02801.x · Cited by 52
Huang, L. Z., & Winzer‐Serhan, U. H. (2006) · Brain Research · doi:10.1016/j.brainres.2006.06.084 · Cited by 52
Drenan, R. M., & Lester, H. A. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004671 · Cited by 55
Acetamiprid Accumulates in Different Amounts in Murine Brain Regions
Terayama, H., Endo, H., Tsukamoto, H., Matsumoto, K., Umezu, M., Kanazawa, T., Ito, M., Sato, T., Naito, M., Kawakami, S., et al. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13100937 · Cited by 50
Nicotinic Cholinergic Receptors in the Rat Retina: Simple and Mixed Heteromeric Subtypes
Marritt, A. M., Cox, B. C., Yasuda, R. P., McIntosh, J. M., Xiao, Y., Wolfe, B. B., & Kellar, K. J. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.012369 · Cited by 50
Self-citationWilkins, L. H., Haubner, A. J., Ayers, J. T., Crooks, P. A., & Dwoskin, L. P. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1088 · Cited by 50
A new outlook on cholinergic interneurons in Parkinson’s disease and L-DOPA-induced dyskinesia
Conti, M. M., Chambers, N., & Bishop, C. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.05.021 · Cited by 50
Acetylcholine protection of adult pig retinal ganglion cells from glutamate-induced excitotoxicity.
Wehrwein, E., Thompson, S. A., Coulibaly, S. F., Linn, D., & Linn, C. (2004) · Investigative Ophthalmology and Visual Science · doi:10.1167/iovs.03-0406 · Cited by 55
Chen, Y., Sharples, T. J. W., Phillips, K. G., Benedetti, G., Broad, L. M., Zwart, R., & Sher, E. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00189-8 · Cited by 45
Cotinine selectively activates a subpopulation of α3/α6β2* nicotinic receptors in monkey striatum
O’Leary, K., Parameswaran, N., McIntosh, J. M., & Quik, M. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.136838 · Cited by 45
Self-citationVisanji, N. P., O’Neill, M. J., & Duty, S. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.04.015 · Cited by 45
Grinevich, V. P., Letchworth, S. R., Lindenberger, K. A., Ménager, J., Mary, V., Sadieva, K. A., Buhlman, L. M., Böhme, G. A., Pradier, L., Bénavidès, J., et al. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075069 · Cited by 44
Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents
Dwoskin, L. P., Sumithran, S. P., Zhu, J., Deaciuc, A. G., Ayers, J. T., & Crooks, P. A. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.10.073 · Cited by 44
Quik, M., Campos, C., Bordia, T., Strachan, J., Zhang, J., McIntosh, J. M., Letchworth, S. R., & Green-Jordan, K. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.038 · Cited by 43
Self-citationExpression of mutant β2 nicotinic receptors during development is crucial for epileptogenesis
Manfredi, I., Zani, A., Rampoldi, L., Pegorini, S., Bernascone, I., Moretti, M., Gotti, C., Croci, L., Consalez, G. G., Ferini‐Strambi, L., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp004 · Cited by 45
Self-citationChipana, C., Camarasa, J., Pubill, D., & Escubedo, E. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.05.032 · Cited by 43
Luetje, C. W. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.6.1333 · Cited by 43
Schilaty, N. D., Hedges, D. M., Jang, E. Y., Folsom, R. J., Yorgason, J. T., McIntosh, J. M., & Steffensen, S. C. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.211490 · Cited by 47
Self-citationDopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection
Bono, F., Mutti, V., Fiorentini, C., & Missale, C. (2020) · Biomolecules · doi:10.3390/biom10071016 · Cited by 43
Krishnaswamy, A., & Cooper, E. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2011.214007 · Cited by 43
Quarta, D., Naylor, C. G., & Stolerman, I. P. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0802-3 · Cited by 41
Pakkanen, J. S., Jokitalo, E., & Tuominen, R. K. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04105.x · Cited by 41
McCallum, S. E., Parameswaran, N., Bordia, T., Fan, H., McIntosh, J. M., & Quik, M. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104414 · Cited by 48
Self-citationPharmacogenetics of smoking cessation: role of nicotine target and metabolism genes
Gold, A. B., & Lerman, C. E. (2012) · Human Genetics · doi:10.1007/s00439-012-1143-9 · Cited by 41
Jaworowska, E., Trubicka, J., Lener, M. R., Masojć, B., Złowocka-Perłowska, E., McKay, J., Renard, H., Oszutowska–Mazurek, D., Wokołorczyk, D., Lubiński, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025057 · Cited by 41
Grilli, M., Summa, M., Salamone, A., Olivero, G., Zappettini, S., Prisco, S. D., Feligioni, M., Usai, C., Pittaluga, A., & Marchi, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.049 · Cited by 40
Pucci, L., Grazioso, G., Dallanoce, C., Rizzi, L., Micheli, C. D., Clementi, F., Bertrand, S., Bertrand, D., Longhi, R., Amici, M. D., et al. (2011) · The FASEB Journal · doi:10.1096/fj.10-179853 · Cited by 40
Self-citationNew insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice
Bağdaş, D., Alkhlaif, Y., Jackson, A. B., Carroll, F. I., Ditre, J. W., & Damaj, M. I. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.025 · Cited by 42
Nasehi, M., Sharifi, S., & Zarrindast, M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111421972 · Cited by 39
Garção, P., Szabó, E. C., Wopereis, S., de Castro, A. A., Tomé, Â. R., Prediger, R. D., Cunha, R. A., Agostinho, P. M., & Köfalvi, A. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12234 · Cited by 40
Ward, R. J., Lallemand, F., Witte, P. D., & Dexter, D. T. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.03.003 · Cited by 38
Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse
Skike, C. E. V., Maggio, S. E., Reynolds, A. R., Casey, E. M., Bardo, M. T., Dwoskin, L. P., Prendergast, M., & Nixon, K. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.004 · Cited by 43
Signore, A. D., Gotti, C., Rizzo, A., Moretti, M., & Paggi, P. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.2.138 · Cited by 39
Self-citationAcharya, S., & Kim, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094299 · Cited by 40
Azam, L., & McIntosh, J. M. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.071456 · Cited by 37
Self-citationZanetti, L., Picciotto, M. R., & Zoli, M. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0598-6 · Cited by 37
Self-citationParish, C. L., Nunan, J., Finkelstein, D. I., McNamara, F. N., Wong, J. Y. F., Waddington, J. L., Brown, R. M., Lawrence, A. J., Horne, M. K., & Drago, J. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.004820 · Cited by 38
Dwoskin, L. P., Wooters, T. E., Sumithran, S. P., Siripurapu, K. B., Joyce, B. M., Lockman, P. R., Manda, V. K., Ayers, J. T., Zhang, Z., Deaciuc, A. G., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.136630 · Cited by 39
Self-citationLomazzo, E., Hussmann, G. P., Wolfe, B. B., Yasuda, R. P., Perry, D. C., & Kellar, K. J. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07408.x · Cited by 37
Development of Novel Pharmacotherapeutics for Tobacco Dependence: Progress and Future Directions
Harmey, D., Griffin, P. R., & Kenny, P. J. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/nts201 · Cited by 37
Sidhpura, N., Redfern, P. H., Rowley, H. L., Heal, D. J., & Wonnacott, S. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.025 · Cited by 37
Targeting Nicotinic Receptors for Parkinson's Disease Therapy
Quik, M., Bordia, T., Huang, L. Z., & Perez, X. A. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711797247849 · Cited by 38
Grilli, M., Zappettini, S., Raiteri, L., & Marchi, M. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.10.014 · Cited by 36
The Cholinergic System as a Treatment Target for Opioid Use Disorder
Jensen, K. P., DeVito, E. E., Yip, S. W., Carroll, K. M., & Sofuoglu, M. (2018) · CNS Drugs · doi:10.1007/s40263-018-0572-y · Cited by 37
The retrotrapezoid nucleus and the neuromodulation of breathing
Moreira, T. S., Sobrinho, C. R., Falquetto, B., Oliveira, L. M., Lima, J. D., Mulkey, D. K., & Takakura, A. C. T. (2020) · Journal of Neurophysiology · doi:10.1152/jn.00497.2020 · Cited by 36
Functional effects of antibodies against non-neuronal nicotinic acetylcholine receptors
Lykhmus, O., Koval, L., Pavlovych, S. I., Zouridakis, M., Zisimopoulou, P., Tzartos, S. J., Tsetlin, V. I., Volpina, O. M., Cloëz-Tayarani, I., Комісаренко, С. В., et al. (2009) · Immunology Letters · doi:10.1016/j.imlet.2009.11.006 · Cited by 35
Metadata
- Authors
- Zoli, M., Moretti, M., Zanardi, A., McIntosh, J. M., Clementi, F., & Gotti, C.
- Affiliations
- University of Milan (IT)
- University of Modena and Reggio Emilia (IT)
- University of Utah (US)
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2002-10-15
- Volume
- 22
- Issue
- 20
- Pages
- 8785-8789
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6757689
- OpenAlex
- W2162000418
- Cited by
- 407
- References
- 28
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 3 · 2023: 5 · 2022: 7 · 2021: 11 · 2020: 10 · 2019: 13 · 2018: 15 · 2017: 9 · 2016: 16 · 2015: 13 · 2014: 16 · 2013: 10 · 2012: 14
- FWCI
- 8.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neuroscience (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Funders
- National Institutes of Health
- National Institute of Mental Health (MH53631, R01MH053631, R29MH053631)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- nicotinic acetylcholine receptors, dopaminergic terminals, striatum, caudate-putamen, alpha4beta2 nAChR, alpha-conotoxin MII, methyllycaconitine, nicotine, 6-hydroxydopamine lesion, Parkinson's disease
- MeSH terms
- Animals, Binding, Competitive, Corpus Striatum, Dopamine, Ligands, Male, Precipitin Tests, Receptors, Nicotinic, Specific Pathogen-Free Organisms, Oxidopamine, Rats, Sprague-Dawley, Presynaptic Terminals, Nicotinic Agonists, Nicotinic Antagonists, Dopamine Uptake Inhibitors, Protein Subunits, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review